Clinical trial
Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine…
NCT00451100 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00451100 |
|---|---|
| Title | Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931) |
| Official title | Comparison of Rocuronium and Org25969 With Cisatracurium and Neostigmine When Neuromuscular Block is Reversed at Reappearance of T2 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anesthesia, General |
| Intervention type | Drug |
| Interventions | Sugammadex, neostigmine |
| Enrollment | 84 |
| Start date | Nov 10, 2005 |
| Primary completion | May 22, 2006 |
| Completion | Aug 29, 2006 |
| First posted | Mar 23, 2007 |
| Last update posted | Nov 15, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: